What patent does acoramidis relate to?
“Acoramidis” is associated with drug-development IP (composition-of-matter and related method/use patents) for treating transthyretin amyloidosis. The specific patent numbers, jurisdictions, and remaining term depend on which filing you mean (for example, primary composition claims vs later-life improvements or use claims).
To answer accurately, you need one of the following:
- the patent number (or a link), or
- the country/region (US, EP, UK, etc.), or
- whether you mean the first (earliest) patent, the most recent patent, or the one driving market exclusivity for acoramidis.
When does the acoramidis patent expire?
Patent expiration dates are determined by the jurisdiction and the specific patent family, including:
- the effective filing date (typical baseline: 20 years from the earliest priority filing),
- any patent-term adjustments or extensions allowed in that country,
- and whether separate patents cover different aspects (drug substance vs formulation vs methods of treatment).
Without the exact patent family or jurisdiction, a single expiration date for “the acoramidis patent” can’t be stated reliably.
Are there multiple patents for acoramidis, or just one?
Usually there are multiple patents tied to one medicine. For acoramidis, different patents can cover:
- the chemical entity (composition),
- specific crystalline forms, formulations, or dosing,
- and therapeutic methods (use in specific diseases or patient groups).
That means one patent can expire while others remain in force, which affects whether generics/biosimilars can launch and what claims they can challenge.
Can competitors launch if one acoramidis patent expires?
In practice, even if one patent expires, competitors may still be blocked by other still-active patents (for example, method-of-use claims or formulation-related claims). Launch timing often turns on the “patent landscape” in each jurisdiction, not a single headline date.
What does “patent” mean here versus exclusivity (regulatory exclusivity)?
Patent term and regulatory exclusivity are different:
- Patents are enforceable IP rights that can be infringed.
- Regulatory exclusivity (where applicable) can delay approval even if a patent expires, depending on the drug’s approval framework in that country.
To pinpoint launch/expiry risk for acoramidis, you need both the relevant patent(s) and the regulatory exclusivity rules in the target market.
Which acoramidis patents are being challenged or litigated?
If you’re tracking generic or competitor risk, the most useful items are:
- the asserted patents in litigation,
- the district/court and case number,
- and which country market the dispute targets.
If you share a patent number or a jurisdiction, I can map what that specific patent covers and what it likely blocks.
What I need from you to give the exact acoramidis patent details
Reply with any one of these and I’ll narrow to the correct patent and provide the likely expiration/term:
- Patent number (US/EP/WO/etc.)
- Jurisdiction (US or Europe, for example)
- A link to the patent record
- The brand name/company filing (if you have it)
Sources
No sources were provided in the prompt, so I can’t cite specific acoramidis patent documents or expiration dates yet.